Trial reportThe international journal of neuropsychopharmacology2016
Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.
Open access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in The international journal of neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies.Translational psychiatry · 2025Pooled it
- Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Hallucinations and Hallucinogens: Psychopathology or Wisdom?Culture, medicine and psychiatry · 2023Article
- The Altered States Database: Psychometric data from a systematic literature review.Scientific data · 2022Article
- The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A.The international journal of neuropsychopharmacology · 2022Article
- The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.Handbook of experimental pharmacology · 2022Review
- Pharmacokinetics and Pharmacodynamics of Salvinorin A andPharmaceuticals (Basel, Switzerland) · 2021Review
- Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics.Journal of psychiatry and brain science · 2021Article
- The drug likeness analysis of anti-inflammatory clerodane diterpenoids.Chinese medicine · 2020Review
- Neuroendocrine effects of naltrexone versus nalmefene in humans.Human psychopharmacology · 2020Article
- Medications for substance use disorders (SUD): emerging approaches.Expert opinion on emerging drugs · 2017Review
- "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".Psychopharmacology · 2017Article
- Clinical applications of hallucinogens: A review.Experimental and clinical psychopharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Ana Elda MaquedaHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Marta ValleHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Peter H AddyHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Rosa Maria AntonijoanHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Montserrat PuntesHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Jimena CoimbraHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Maria Rosa BallesterHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Maite GarridoHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Mireia GonzálezHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Judit ClaramuntHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Steven BarkerHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Izabela LomnickaHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Marian WaguespackHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Matthew W JohnsonHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Roland R GriffithsHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths).
Jordi RibaHuman Neuropsychopharmacology Group, Sant Pau Institute of Biomedical Research (IIB-Sant Pau), Sant Antoni María Claret, Barcelona, Spain (Ms Maqueda and Dr Riba); Centre d'Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Dr Valle, Dr Puntes, Dr Coimbra, Ms Ballester, Ms Garrido, Ms González, Ms Claramunt, and Dr Riba); Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Valle, Antonijoan, and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, Antonijoan, and Riba); Pharmacokinetic and Pharmacodynamic Modelling and Simulation, IIB Sant Pau, Sant Antoni María Claret, Barcelona, Spain (Dr Valle); Medical Informatics, VA Connecticut Healthcare System, West Haven, CT (Dr Addy); Medical Informatics, Yale University School of Medicine, New Haven, CT (Dr Addy); Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at River Road, Baton Rouge, LA (Drs Barker, Lomnicka, and Waguespack); Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (Drs Johnson and Griffiths); Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD (Dr Griffiths). jriba@santpau.cat.
Louisiana State University · USUniversitat Autònoma de Barcelona · ESVA Connecticut Healthcare System · USCentro de Investigación Biomédica en Red de Salud Mental · ESYale University · USHospital de Sant Pau · ESJohns Hopkins University · US
Funding
Human Clinical Pharmacology of Emerging Drugs of Abuse (Club Drugs)R01DA003889 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GRIFFITHS, ROLAND R · 1985 to 2017
$7.6MNIDA NIH HHS R01 DA003889
Abstract
backgroundSalvinorin-A is a terpene found in the leaves of the plant Salvia divinorum. When administered to humans, salvinorin-A induces an intense but short-lasting modified state of awareness, sharing features with those induced by the classical serotonin-2A receptor agonist psychedelics. However, unlike substances such as psilocybin or mescaline, salvinorin-A shows agonist activity at the kappa-opioid receptor rather than at the serotonin-2A receptor. Here, we assessed the involvement of kappa-opioid receptor and serotonin-2A agonism in the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans.
methodsWe conducted a placebo-controlled, randomized, double-blind study with 2 groups of 12 healthy volunteers with experience with psychedelic drugs. There were 4 experimental sessions. In group 1, participants received the following treatment combinations: placebo+placebo, placebo+salvinorin-A, naltrexone+placebo, and naltrexone+salvinorin-A. Naltrexone, a nonspecific opioid receptor antagonist, was administered at a dose of 50mg orally. In group 2, participants received the treatment combinations: placebo+placebo, placebo+salvinorin-A, ketanserin+placebo, and ketanserin+salvinorin-A. Ketanserin, a selective serotonin-2A antagonist, was administered at a dose of 40mg orally.
resultsInhalation of 1mg of vaporized salvinorin-A led to maximum plasma concentrations at 1 and 2 minutes after dosing. When administered alone, salvinorin-A severely reduced external sensory perception and induced intense visual and auditory modifications, increased systolic blood pressure, and cortisol and prolactin release. These effects were effectively blocked by naltrexone, but not by ketanserin.
conclusionsResults support kappa opioid receptor agonism as the mechanism of action underlying the subjective and physiological effects of salvinorin-A in humans and rule out the involvement of a serotonin-2A-mediated mechanism.
Indexed as
AdultBlood PressureDiterpenes, ClerodaneDouble-Blind MethodDrug InteractionsFemaleHallucinogensHealthy VolunteersHumansHydrocortisoneKetanserinMaleNaltrexoneNarcotic AntagonistsPerceptionProlactinDiterpenes, ClerodaneHallucinogensHydrocortisoneKetanserinNaltrexoneNarcotic AntagonistsProlactinsalvinorin ASerotonin Antagonistshuman pharmacologykappa opioid receptor antagonismketanserinnaltrexoneSalvinorin-Aserotonin-2A antagonism
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.